X0306 4 2020-11-09 false 0000897448 AMARIN CORP PLC\UK AMRN 0001199637 THERO JOHN F C/O AMARIN PHARMA, INC. 440 US HIGHWAY 22 BRIDGEWATER NJ 08807 true true false false President and CEO Ordinary Shares 2020-11-09 4 M false 134739.00 3.40 A 2691144.00 D Ordinary Shares 2020-11-10 4 M false 615261.00 3.40 A 3306405.00 D Ordinary Shares 2020-11-10 4 S false 153840.00 4.134 D 3152565.00 D Ordinary Shares 2020-11-11 4 S false 413565.00 4.0651 D 2739000.00 D Stock Option (Right to Buy) 3.40 2020-11-09 4 M false 134739.00 0.00 D 2020-11-10 Ordinary Shares 134739.00 615261.00 D Stock Option (Right to Buy) 3.40 2020-11-10 4 M false 615261.00 0.00 D 2020-11-10 Ordinary Shares 615261.00 0.00 D Acquisitions reported in this Form 4 pertain to exercises of stock options scheduled to expire on Nov. 10, 2020. In the first of the reported acquisitions, dated Nov. 9, 2020, 134,739 shares were acquired for $500,000, in cash, covering the exercise price of the stock options and the related taxes. The second acquisition, dated Nov. 10, 2020, involved shares acquired by the Reporting Person for cash offset by proceeds from sales of a portion of the acquired shares with the net remaining shares, after paying for cost for this second acquisition including taxes, added to the holdings of the Reporting Person. The result of these transactions, for cash and other consideration paid, was a net increase in shares held by the Reporting Person of 182,595 shares. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.11 to $4.16, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff at the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.01 to $4.14, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff at the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Please see the section titled "Remarks" below for additional information. The stock option granted to the Reporting Person is fully vested as of the date hereof. As of the date of this Form 4, the Reporting Person owns or holds the right to acquire an aggregate of 8,957,185 Ordinary Shares of the Issuer in the form of Ordinary Shares, stock options and RSUs granted under the Plan, including but not limited to certain performance-based RSUs that are earned only if product revenues reach pre-defined annual milestone levels and, in certain cases, then vest only if the recipient remains with the company for an extended period of time. /s/ John F. Thero 2020-11-12